Coverage of Vytorin Cancer Data Fades Quickly

Just when it seemed Vytorin was getting back on track, results of a study showing that patients taking the cholesterol-fighter had more cancers than those taking a placebo surprised everyone last month. Merck and Schering-Plough, which jointly market the medicine, delayed their second-quarter earnings announcements so that scientists involved in analyzing the study could present [...]